TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Race Oncology Ltd. ( (AU:RAC) ) just unveiled an update.
Race Oncology Ltd has appointed Professor Laurence Hurley, a distinguished oncology drug developer, to its Scientific Advisory Board. Prof Hurley, known for his pioneering work in G-quadruplex targeting drugs, will provide valuable insights into the development of Race’s G4-targeting agents, potentially enhancing the company’s position in the oncology drug market. This move is expected to strengthen Race’s research and development efforts, potentially leading to significant advancements in cancer treatment.
More about Race Oncology Ltd.
Race Oncology Ltd is a company in the pharmaceutical industry, focusing on the development of oncology drugs. The company is known for its work on G-quadruplex targeting drugs, including RCDS1 (E,E-bisantrene) and RC220, which are aimed at treating various cancers.
Average Trading Volume: 369,828
Technical Sentiment Signal: Buy
Current Market Cap: A$684.8M
For an in-depth examination of RAC stock, go to TipRanks’ Overview page.